Histone deacetylase inhibitors in non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 16 SUPPL. 5, 2012, Pages

  Witta, Samir ^a  

^a Mountain Blue Cancer Care Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; PACLITAXEL; PLACEBO; PROTEIN KINASE B; RAF PROTEIN; ROMIDEPSIN; TAXANE DERIVATIVE; UVOMORULIN; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; EPIGENETICS; FATIGUE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION; TREATMENT RESPONSE;

EID: 84870414424     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31826df29c     Document Type: Article

References (15)

1. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-5552.
2. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005;363:15-23.
3. Liang D, Kong X, Sang N. Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle 2006;5:2430-2435.
4. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005;280:26729-26734.
5. Nolan L, Johnson PW, Ganesan A, Packham G, Crabb SJ. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 2008;99:689-694.
6. Zuco V, De Cesare M, Cincinelli R, et al. Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo. PLoS ONE 2011;6:e29085.
7. Hershberger PK, Gregg J, Pacheco C, Winton J, Richard J, Traxler G. Larval Pacific herring, Clupea pallasii (Valenciennes), are highly susceptible to viral haemorrhagic septicaemia and survivors are partially protected after their metamorphosis to juveniles. J Fish Dis 2007;30: 445-458.
8. Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010;28:56-62.
9. Sato T, Suzuki M, Sato Y, Echigo S, Rikiishi H. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 2006;28:1233-1241.
10. Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA. Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer 2010;126:743-755.
11. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-1128.
12. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598-607.
13. Zhang W, Peyton M, Xie Y, et al. Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. J Thorac Oncol 2009;4:161-166.
14. Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66:944-950.
15. Witta SE, Jotte RM, Kondori K, et al. Randomized phase ii trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy J Clin Oncol 2012;38:9411.